Xigris Withdrawal’s Impact On Lilly Is Minimal, But Leaves BioCritica Pondering Its Future
Key business questions linger following Eli Lilly & Co.’s announcement on Oct. 25 that it is withdrawing its troubled sepsis drug Xigris from all markets: What’s the impact of the action on Lilly, and what’s next for BioCritica Inc., the start-up formed largely to take over the drug’s commercialization?
You may also be interested in...
Lilly's earnings are in line with analyst expectations, but higher costs cut into profits as the company prepares for a revenue decline.
Initial focus of the private biotech will be on continued development and commercialization of Xigris for sepsis; investment backers are NovaQuest Capital and Care Capital.
In this era of health care reform, critical care medicine remains a strong market for innovative technologies that can improve patient outcomes, shorten ICU stays, and ultimately reduce the overall cost of care. Within this space, one segment that is ripe for innovation is the market for severe sepsis products.Although the last 20 years have seen advances in treatment and a marked increase in the understanding of sepsis and septic shock, severe sepsis remains one of the most significant challenges in critical care today.